EQUITY AND EARNINGS PER COMMON SHARE - Schedule of Noncontrolling Interests (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Net income attributable to Sempra	$ 1,837	$ 2,862	$ 3,075
Increase in shareholders’ equity from investor equity subscription	16		0
Increase in shareholders' equity from allocation of interests	1,073		0
Decrease in shareholders’ equity for sales of NCI	0		(49)
Net transfers (to) from CRNCI and NCI	1,089		(49)
Change from net income attributable to Sempra and transfers (to) from CRNCI and NCI	$ 2,926		$ 3,026